Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : EU regulators charge Teva over pay-for-delay drug deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2017 | 01:36pm CEST
A building belonging to Teva Pharmaceutical Industries, the world's biggest generic drugmaker and Israel's largest company, is seen in Jerusalem

EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

EU antitrust regulators charged Israeli drugmaker Teva (>> Teva Pharmaceutical Industries Limited) <TEVA.N> on Monday with doing an illegal deal with Cephalon to delay selling a cheaper generic version of the latter's sleep disorder drug, putting it at risk of a fine.

The crackdown by the European Commission follows fines against scores of companies including Denmark's Lundbeck, U.S. giant Johnson & Johnson and France's Servier in recent years over similar deals.

The EU competition enforcer's 2009 inquiry into the sector showed that so-called pay-for-delay deals cost European consumers billions of euros.

Teva, the world's biggest generic drugmaker, reached the deal with Cephalon as part of a settlement to end a lawsuit over alleged infringement of Cephalon's patents on the blockbuster drug. This involved cash payments from Cephalon, which Teva later acquired in 2011.

The Commission said the deal may have pushed up prices of the drug, modafinil.

"The patent settlement agreement between Cephalon and Teva may have caused substantial harm to EU patients and health service budgets," the EU competition enforcer said in a statement.

Teva said it strongly disagreed with the Commission's analysis on such deals.

"We do not believe that Cephalon and Teva entered into any anti-competitive behavior," the company said.

Teva, which can ask for a closed-door hearing to defend its case, can be fined up to 10 percent of its global turnover if found guilty of breaching EU antitrust rules. The company made $21.9 billion of revenue in 2016.

It was fined 15.6 million euros ($17.9 million) in 2014 for an illegal deal with Servier.

The Commission in May sent a warning shot to the sector by opening an investigation into alleged excessive pricing by South Africa's Aspen Pharmacare (>> Aspen Pharmacare Holdings Limited) for five cancer medicines.

(Reporting by Foo Yun Chee; Additional reporting by Ari Rabinovitch in Jerusalem; Editing by Philip Blenkinsop and Mark Potter)

By Foo Yun Chee

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TEVA PHARMACEUTICAL INDUST
09/21 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Lundin Law PC Announces a Securities Clas..
09/21 TEVA PHARMACEUTICAL INDUSTRIES : Glancy Prongay & Murray Announces the Filing of..
09/21 TEVA PHARMACEUTICAL INDUSTRIES : Announces Sale of PARAGARD® intrauterine copper..
09/21 TEVA PHARMACEUTICAL INDUSTRIES : Receives FDA Priority Review for First Line Use..
09/21 TEVA PHARMACEUTICAL INDUSTRIES : Showcases Data Demonstrating Potential of Frema..
09/20 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Khang & Khang LLP Announces Securities Cl..
09/20DJMakers Of Opioids Are Asked For Data -- WSJ
09/19 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Lundin Law PC Announces a Securities Clas..
09/19DJStates Push Ahead With Investigation Into Opioid Painkillers
09/19 AZRIELI : Teva in talks with Azrieli to rent new Petah Tikva HQ
More news
News from SeekingAlpha
09/20 YOUR DAILY PHARMA SCOOP : Geron's Growth Potential, Ipsen's Xarmelo Approval, GS..
09/19 Teva - More Sales, Mind The Proceeds
09/19 State AGs gang up on opioid makers, 41 now in coalition
09/19 Teva teams up with Nuvelution Pharma to accelerate development of Austedo for..
09/19 MYLAN : Time To Sell?
Financials ($)
Sales 2017 23 033 M
EBIT 2017 6 610 M
Net income 2017 -
Debt 2017 31 255 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,12x
EV / Sales 2018 1,99x
Capitalization 17 501 M
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 31,3 $
Spread / Average Target 80%
Managers
NameTitle
Kåre Schultz President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael R. Hayden President-Global Research & Development
Roger Abravanel Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED-56.18%17 501
JOHNSON & JOHNSON15.63%353 617
NOVARTIS11.88%223 850
ROCHE HOLDING LTD.6.19%221 926
PFIZER10.81%214 206
MERCK AND COMPANY11.75%178 914